Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL: Seladelpar in Primary Biliary Cholangitis
NCT06060665Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Started Sep 2023; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06060665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060665.